Proof of efficacy for Seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis non-responsive to ursodeoxycholic acid: results of an international Phase 2 randomised controlled clinical study
Gideon M. Hirschfield(University of Birmingham), DE Jones, Charles A. McWherter(CymaBay Therapeutics (United States)), Alexandra Steinberg(CymaBay Therapeutics (United States)), Pol Boudes(CymaBay Therapeutics (United States)), Michal Galamboš, Mark G. Swain(University of Calgary), Yu-Seong Choi, R.L. Martin, Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Harinder Chera(CymaBay Therapeutics (United States)), M. Varga, Christopher L. Bowlus(University of Padua)
Cited by 1
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis
|Hepatology|2015|348
Active Crohnʼs disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora
|Inflammatory Bowel Diseases|2007|273